08/20/2026
❗ Throwback Thursday ❗
Picking up where we left off last week, the second part of the EADV 2025 symposium covered JAK inhibitors, dupilumab, methotrexate, and the risks of unmasking CTCL in AD patients, with practical guidance on biopsy before biologics, monitoring for red flags, and the diagnostic algorithm for differentiating severe eczema from early lymphoma.
EADV 2025 PART 2